Key result
Higher plasma thrombomodulin is linked to increased all-cause and vascular mortality during long-term anticoagulation.
Why the study?
Do plasma levels of thrombomodulin predict mortality in patients on long-term anticoagulant treatment?
Cohort (n=209)
Do plasma levels of thrombomodulin predict mortality in patients on long-term anticoagulant treatment?
Increased plasma thrombomodulin levels independently predict all-cause and vascular mortality in patients on long-term anticoagulation.
Answers are grounded in this paper and cite their sources.
Should not yet guide anticoagulation decisions; hypothesis-generating for thrombomodulin in mortality risk stratification.
BACKGROUND: The aim of the study was to test if plasma levels of thrombomodulin could predict mortality in 209 patients on long-term anticoagulant treatment followed up for 3.8 years. METHODS AND RESULTS: The thrombomodulin level was 60.9 +/- 29.8 micrograms.l-1 for all 45 patients who died and 60.5 +/- 30.5 micrograms.l-1 for the 38 vascular deaths, compared to 52.3 +/- 20.7 micrograms.l-1 for the 164 survivors. We found that, in Cox regression analyses, all-cause (P = 0.025) and vascular mortality (P = 0.042) was significantly and independently associated with increased levels of thrombomodulin. CONCLUSIONS: The level of plasma thrombomodulin can predict all-cause and vascular mortality in patients on long-term anticoagulant treatment.
No takes yet. Share an insight, caveat, or question.
Jansson et al. (1996) conducted a cohort in Patients on long-term anticoagulant treatment (n=209). Plasma thrombomodulin levels was evaluated on All-cause mortality (p=0.025). Increased levels of plasma thrombomodulin were associated with all-cause and vascular mortality in patients on long-term anticoagulant treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: